Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism –– IND-Enabling Studies ...
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $...
To regain compliance with the Minimum Bid Price Requirement, the Company’s common stock was required to maintain a closing bid ...
Jefferies analyst Roger Song maintains Nektar Therapeutics (NASDAQ:NKTR) with a Hold and raises the price target from $0.5 t...
Nektar Therapeutics (NASDAQ:NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, tod...
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $...
